Clinical Trial Update: ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing ATG with basiliximab in kidney transplant recipients with low immunological risk and high susceptibility to delayed graft function was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Simulect (Basiliximab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Nantes University Hospital | Conditions: Kidney Transplantation | Phase 4 | Status: TERMINATED